Targets › PKLR
4 programs from 4 companies in 19 trials: 12 Phase 3, 5 Phase 2, 2 Phase 1; Hematology; next expected readout Mar 2027.
Pyruvate kinase that catalyzes the conversion of phosphoenolpyruvate to pyruvate with the synthesis of ATP, and which plays a key role in glycolysis. Also produces the side product 2-phospholactate which can inhibit fructose-2,6-bisphosphate production. 2-phospholactate can be dephosphorylated by PGP which prevents the inhibition of fructose-2,6-bisphosphate production and allows glycolysis to occur. (UniProt, P30613)
Open in Phaseline: the race on PKLR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Forma Therapeutics | Etavopivat Pyruvate kinase isozymes R/L activator | PKLR | Phase 3 | Sickle Cell Disease | Mar 2027 |
| Novo Nordisk | Etavopivat Pyruvate kinase isozymes R/L activator | PKLR | Phase 3 | Sickle Cell Disease | Aug 2027 |
| Agios Pharmaceuticals | Mitapivat Pyruvate kinase isozymes R/L activator | PKLR | Phase 3 | Non-Transfusion-dependent Alpha-Thalassemia; Transfusion-dependent Alpha-Thalassemia; Pediatric Pyruvate Kinase Deficiency; Sickle Cell Disease … | Dec 2028 |
| ScinnoHub Pharmaceutical | SNH-119014 Pyruvate kinase red blood cell isozyme (PKR) agonist | PKLR | Phase 1 | Hemoglobinopathy | – |
Sickle Cell Disease (10) Non-Transfusion-dependent Alpha-Thalassemia (2) Transfusion-dependent Alpha-Thalassemia (2) Pediatric Pyruvate Kinase Deficiency (2) Thalassemia (1) Anemia (1) Hemoglobinopathy (1)
small molecule (4)
Forma Therapeutics (1) Agios Pharmaceuticals (1) ScinnoHub Pharmaceutical (1) Novo Nordisk (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.